CGRP介导的癌痛机制与靶向治疗研究进展OA

Calcitonin gene-related peptide(CGRP)exerts a central-peripheral synergistic amplification effect in the development and maintenance of cancer pain.This effect is mediated through the activation of signaling pathways,including NGF and BMP2,leading to increased sensory nerve excitability,the promotion of peripheral and central sensitization,and the formation of a"pain-tumor progression"positive feedback loop with the tumor microenvironment.Preclinical evidence has demonstrated the significant analgesic and anti-tumor potential of CGRP antagonists in models including breast cancer,oral cancer,and pancreatic cancer,among others.Furthermore,CGRP levels are closely correlated with cancer pain intensity,suggesting its potential value as a biomarker and intervention target for targeted cancer pain therapy.This review summarizes the mechanistic roles of CGRP in cancer pain and tumor progression,as well as recent advances in related therapeutic research,and explores future strategies for cancer pain management through targeting the CGRP pathway in combination with existing treatment modalities.